These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 36407316)
1. Positive Huang S; Qi M; Tian T; Dai H; Tang Y; Huang R Front Endocrinol (Lausanne); 2022; 13():959089. PubMed ID: 36407316 [TBL] [Abstract][Full Text] [Related]
2. The Genetic Duet of Liu J; Liu R; Shen X; Zhu G; Li B; Xing M J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570 [No Abstract] [Full Text] [Related]
3. BRAFV600E Mutation Does Not Significantly Affect the Efficacy of Radioiodine Therapy in Patients With Papillary Thyroid Carcinoma Without Known Distant Metastases. Shen G; Kou Y; Liu B; Huang R; Kuang A Clin Nucl Med; 2018 Jul; 43(7):e215-e219. PubMed ID: 29762246 [TBL] [Abstract][Full Text] [Related]
4. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy. Li J; Liang J; Zhao T; Lin Y Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618 [TBL] [Abstract][Full Text] [Related]
5. BRAFV600E mutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer. Campennì A; Ruggeri RM; Giuffrè G; Siracusa M; Alibrandi A; Cardile D; La Torre F; Lanzafame H; Giacoppo G; Ieni A; Trimarchi F; Tuccari G; Baldari S Nucl Med Commun; 2021 Jun; 42(6):611-618. PubMed ID: 33625185 [TBL] [Abstract][Full Text] [Related]
7. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. Lee YA; Lee H; Im SW; Song YS; Oh DY; Kang HJ; Won JK; Jung KC; Kwon D; Chung EJ; Hah JH; Paeng JC; Kim JH; Choi J; Kim OH; Oh JM; Ahn BC; Wirth LJ; Shin CH; Kim JI; Park YJ J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34237031 [TBL] [Abstract][Full Text] [Related]
8. A different prognostic value of BRAFV600E mutation positivity in various age groups of patients with papillary thyroid cancer. Takacsova E; Kralik R; Waczulikova I; Zavodna K; Kausitz J Neoplasma; 2017; 64(1):156-164. PubMed ID: 27881018 [TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer. Sabet A; Binse I; Grafe H; Ezziddin S; Görges R; Poeppel TD; Bockisch A; Rosenbaum-Krumme SJ Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1988-94. PubMed ID: 27118127 [TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes. Simões-Pereira J; Saramago A; Rodrigues R; Pojo M; Pires C; Horta M; López-Presa D; Rito M; Cabrera R; Ferreira TC; Leite V; Cavaco BM Endocrine; 2024 May; 84(2):625-634. PubMed ID: 38102497 [TBL] [Abstract][Full Text] [Related]
11. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY. Liu YQ; Li H; Liu JR; Lin YS Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228 [No Abstract] [Full Text] [Related]
12. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer. Cao J; Zhu X; Sun Y; Li X; Yun C; Zhang W Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3470-3481. PubMed ID: 35501518 [TBL] [Abstract][Full Text] [Related]
13. Radioactive Iodine-Refractory Pulmonary Metastases of Papillary Thyroid Cancer in Children, Adolescents, and Young Adults. Tian T; Huang S; Dai H; Qi M; Liu B; Huang R J Clin Endocrinol Metab; 2023 Jan; 108(2):306-314. PubMed ID: 36226635 [TBL] [Abstract][Full Text] [Related]
14. Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology. Soe MH; Chiang JM; Flavell RR; Khanafshar E; Mendoza L; Kang H; Liu C J Clin Endocrinol Metab; 2022 Jul; 107(8):e3206-e3216. PubMed ID: 35556126 [TBL] [Abstract][Full Text] [Related]
15. BRAFV600E mutation associated with non-radioiodine-avid status in distant metastatic papillary thyroid carcinoma. Yang K; Wang H; Liang Z; Liang J; Li F; Lin Y Clin Nucl Med; 2014 Aug; 39(8):675-9. PubMed ID: 24978326 [TBL] [Abstract][Full Text] [Related]
16. Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer. Yoon S; An YS; Lee SJ; So EY; Kim JH; Chung YS; Yoon JK Medicine (Baltimore); 2015 Dec; 94(48):e2063. PubMed ID: 26632889 [TBL] [Abstract][Full Text] [Related]
17. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer. Yang X; Li J; Li X; Liang Z; Gao W; Liang J; Cheng S; Lin Y J Nucl Med; 2017 Feb; 58(2):258-265. PubMed ID: 27493271 [TBL] [Abstract][Full Text] [Related]
18. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation. Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027 [TBL] [Abstract][Full Text] [Related]
19. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer. Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243 [TBL] [Abstract][Full Text] [Related]
20. Pulmonary metastases in children and adolescents with papillary thyroid cancer in China: prognostic factors and outcomes from treatment with Zhang XY; Song HJ; Qiu ZL; Shen CT; Chen XY; Sun ZK; Wei WJ; Zhang GQ; Luo QY Endocrine; 2018 Oct; 62(1):149-158. PubMed ID: 30022382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]